Safety and Efficacy of Infliximab Therapy in the Setting of Steroid-Refractory Acute Graft-versus-Host Disease

Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
Fevzi F YalnizMrinal M Patnaik

Abstract

Acute graft-versus-host disease (aGVHD) is the leading cause of morbidity and mortality after allogenic hematopoietic cell transplantation (HCT). Corticosteroids are the first-line treatment; however, less than one-half of patients achieve durable remission. Studies suggest that TNF-α, a cytokine released from the bone marrow during conditioning, is involved in the pathogenesis of aGVHD. We retrospectively evaluated the outcome of anti-TNF-α therapy with infliximab in 35 patients with steroid refractory (SR) aGVHD. Infliximab was administered intravenously at 10 mg/kg for a median of 4 doses (range, 1 to 6) on a weekly basis. The overall response rates were 40% (17% complete response [CR], 23% partial response [PR]) at 4 weeks, 23% (9% CR, 14% PR) at 8 weeks, and 17% (all CR) at 12 weeks. Twenty-nine (83%) patients had infectious complications within 12 weeks of initiation of infliximab. These infections included 40 bacterial infections, 6 invasive fungal infections, and 5 viral reactivations. Twelve patients (34%) died secondary to infections. Overall survival at 12 weeks and 6 months from the start of infliximab therapy was 37% (13 of 35) and 17% (6 of 35), respectively; with most deaths secondary to complications from GVHD a...Continue Reading

References

Dec 14, 1999·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·J L FerraraN J Chao
May 27, 2003·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Robert KorngoldJill Giles-Komar
Sep 26, 2003·American Journal of Hematology·David A JacobsohnGeorgia B Vogelsang
Oct 15, 2003·Blood Reviews·Pavan Reddy, James L M Ferrara
Apr 8, 2004·Blood·Daniel CourielRichard Champlin
May 6, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·R S WallisD O Beenhouwer
Jun 2, 2005·American Journal of Hematology·Michael Koldehoff, Johames L Zakrzewski
Aug 17, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Paul BrassardSamy Suissa
May 22, 2007·Transplant Infectious Disease : an Official Journal of the Transplantation Society·M J PostD Nachbaur
Jul 10, 2007·Bone Marrow Transplantation·B S SleightA L Gilman
Oct 6, 2007·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Jan LinRam Raj Singh
May 9, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Ben De PauwUNKNOWN National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group
Apr 16, 2009·Clinical Microbiology Reviews·Edsel Maurice T Salvana, Robert A Salata
Aug 8, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Joseph PidalaClaudio Anasetti
Nov 10, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Daniel R CourielAmin Alousi
Dec 1, 2009·Bone Marrow Transplantation·S PaczesnyP Reddy
Nov 24, 2011·Advances in Hematology·Jason R WestinDaniel R Couriel
Apr 27, 2012·British Journal of Haematology·Fiona L DignanUNKNOWN British Society for Blood and Marrow Transplantation
Apr 23, 2013·Bone Marrow Transplantation·K JamaniJ Storek
Mar 22, 2014·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Irene S KourbetiEleftherios Mylonakis
Feb 11, 2016·International Journal of Molecular Sciences·Einar S Björnsson
Jan 1, 1997·Hematology·G R HillJ L Ferrara

❮ Previous
Next ❯

Citations

Apr 7, 2020·Expert Review of Hematology·Roman M Shapiro, Joseph H Antin
Apr 16, 2020·Expert Opinion on Investigational Drugs·Sameem M Abedin, Mehdi Hamadani
May 2, 2020·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Eris TollkuciCelalettin Ustun
Jun 4, 2018·Annals of Hematology·Masaharu TamakiYoshinobu Kanda
Feb 27, 2020·Giornale Italiano Di Dermatologia E Venereologia : Organo Ufficiale, Società Italiana Di Dermatologia E Sifilografia·Ara ChoRobert Knobler
Apr 4, 2020·Leukemia·Florent MalardJoycelyn P Y Sim
Nov 2, 2019·Seminars in Immunopathology·Sindhu ThiagarajanKai Hildner
Mar 16, 2018·Frontiers in Immunology·Antonella MancusiAntonio Pierini
Jun 11, 2020·Journal of the National Comprehensive Cancer Network : JNCCN·Ayman SaadLenora Pluchino
Jan 11, 2020·Frontiers in Immunology·Antonella MancusiAntonio Pierini
Mar 30, 2018·Frontiers in Immunology·Benoît L SalomonJosé L Cohen
Dec 5, 2020·Journal of Experimental Pharmacology·Sameem Abedin, Mehdi Hamadani

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.